Q3 Earnings Forecast for ZVRA Issued By William Blair

Key Points

• William Blair estimates Zevra Therapeutics will post Q3 2025 earnings of ($0.06) per share, compared to the consensus estimate of ($1.95) for the full year.
• Zevra Therapeutics reported a quarterly earnings surprise, with earnings of ($0.06) per share beating expectations by $0.15, alongside revenues of $20.40 million.
• Institutional investors are significantly increasing their stakes in Zevra Therapeutics, with notable increases from firms like Adage Capital Partners and AIGH Capital Management.

Zevra Therapeutics, Inc. (NASDAQ:ZVRA - Free Report) - William Blair issued their Q3 2025 earnings per share estimates for Zevra Therapeutics in a note issued to investors on Monday, July 28th. William Blair analyst S. Corwin anticipates that the company will post earnings per share of ($0.06) for the quarter. The consensus estimate for Zevra Therapeutics' current full-year earnings is ($1.95) per share. William Blair also issued estimates for Zevra Therapeutics' Q4 2025 earnings at ($0.05) EPS, Q1 2026 earnings at ($0.04) EPS, Q2 2026 earnings at $0.00 EPS, Q3 2026 earnings at $0.08 EPS and Q4 2026 earnings at $0.14 EPS.

Zevra Therapeutics (NASDAQ:ZVRA - Get Free Report) last posted its earnings results on Tuesday, May 13th. The company reported ($0.06) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.21) by $0.15. The company had revenue of $20.40 million for the quarter, compared to analysts' expectations of $16.96 million. Zevra Therapeutics had a negative return on equity of 201.05% and a negative net margin of 226.78%. During the same period last year, the firm earned ($0.40) earnings per share.

Several other analysts have also recently issued reports on the company. Citigroup reissued an "outperform" rating on shares of Zevra Therapeutics in a research note on Wednesday, May 14th. Cantor Fitzgerald raised their target price on Zevra Therapeutics from $25.00 to $29.00 and gave the stock an "overweight" rating in a research note on Thursday, July 10th. HC Wainwright started coverage on Zevra Therapeutics in a research note on Wednesday, July 2nd. They issued a "buy" rating and a $26.00 target price on the stock. Finally, Wall Street Zen cut Zevra Therapeutics from a "strong-buy" rating to a "buy" rating in a research note on Sunday, July 20th. Nine investment analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company's stock. According to data from MarketBeat, Zevra Therapeutics has a consensus rating of "Buy" and a consensus target price of $23.71.

Zevra Therapeutics Stock Performance

Shares of NASDAQ ZVRA remained flat at $11.11 during trading hours on Thursday. The company had a trading volume of 802,278 shares, compared to its average volume of 1,359,623. The company has a debt-to-equity ratio of 1.46, a quick ratio of 2.93 and a current ratio of 3.02. The stock has a market capitalization of $607.49 million, a PE ratio of -5.85 and a beta of 1.87. Zevra Therapeutics has a 12 month low of $6.19 and a 12 month high of $13.16. The stock has a 50 day moving average price of $10.11 and a 200-day moving average price of $8.55.

Institutional Trading of Zevra Therapeutics

Several large investors have recently bought and sold shares of the company. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its position in Zevra Therapeutics by 6.1% during the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 31,761 shares of the company's stock valued at $238,000 after acquiring an additional 1,812 shares in the last quarter. Invesco Ltd. boosted its position in Zevra Therapeutics by 19.6% during the 4th quarter. Invesco Ltd. now owns 18,384 shares of the company's stock valued at $153,000 after acquiring an additional 3,007 shares in the last quarter. Corebridge Financial Inc. boosted its position in Zevra Therapeutics by 16.9% during the 4th quarter. Corebridge Financial Inc. now owns 26,294 shares of the company's stock valued at $219,000 after acquiring an additional 3,801 shares in the last quarter. Charles Schwab Investment Management Inc. boosted its position in Zevra Therapeutics by 2.6% during the 1st quarter. Charles Schwab Investment Management Inc. now owns 153,331 shares of the company's stock valued at $1,148,000 after acquiring an additional 3,827 shares in the last quarter. Finally, Squarepoint Ops LLC lifted its holdings in shares of Zevra Therapeutics by 36.1% during the fourth quarter. Squarepoint Ops LLC now owns 16,534 shares of the company's stock valued at $138,000 after purchasing an additional 4,384 shares during the last quarter. 35.03% of the stock is owned by institutional investors.

About Zevra Therapeutics

Zevra Therapeutics, Inc discovers and develops various proprietary prodrugs to treat serious medical conditions in the United States. The company develops its products through Ligand Activated Therapy platform. Its lead product candidate is KP1077, consisting of KP1077IH, which is under Phase 2 clinical trial for the treatment of idiopathic hypersomnia, and KP1077N, which is under Phase ½ clinical trial to treat narcolepsy.